A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [1] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
    Disselhorst, M.
    Harms, E.
    Van Tinteren, H.
    Quispel-Janssen, J.
    Monkhorst, K.
    Burgers, S.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
  • [2] A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
    Quispel-Janssen, Josine
    Zago, Giulia
    Schouten, Robert
    Buikhuisen, Wieneke
    Monkhorst, Kim
    Thunissen, Eric
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S292 - S293
  • [3] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [4] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Haakensen, Vilde Drageset
    Nowak, Anna K.
    Ellingsen, Espen Basmo
    Farooqi, Saima Jamil
    Bjaanaes, Maria Moksnes
    Horndalsveen, Henrik
    Mcculloch, Tine
    Grundberg, Oscar
    Cedres, Susana M.
    Helland, Aslaug
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [5] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Vilde Drageset Haakensen
    Anna K. Nowak
    Espen Basmo Ellingsen
    Saima Jamil Farooqi
    Maria Moksnes Bjaanæs
    Henrik Horndalsveen
    Tine Mcculloch
    Oscar Grundberg
    Susana M. Cedres
    Åslaug Helland
    Journal of Translational Medicine, 19
  • [6] Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
    Nakano, T.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Imamura, F.
    Oizumi, S.
    Takahashi, T.
    Takenoyama, M.
    Tanaka, H.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S338 - S338
  • [7] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hasegawa, Hirotaka
    Shitara, Kohei
    Takiguchi, Shuji
    Takiguchi, Noriaki
    Ito, Seiji
    Kochi, Mitsugu
    Horinouchi, Hidehito
    Kinoshita, Takahiro
    Yoshikawa, Takaki
    Muro, Kei
    Nishikawa, Hiroyoshi
    Suna, Hideaki
    Kodera, Yasuhiro
    GASTRIC CANCER, 2022, 25 (03) : 619 - 628
  • [8] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hirotaka Hasegawa
    Kohei Shitara
    Shuji Takiguchi
    Noriaki Takiguchi
    Seiji Ito
    Mitsugu Kochi
    Hidehito Horinouchi
    Takahiro Kinoshita
    Takaki Yoshikawa
    Kei Muro
    Hiroyoshi Nishikawa
    Hideaki Suna
    Yasuhiro Kodera
    Gastric Cancer, 2022, 25 : 619 - 628
  • [9] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [10] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
12345